CDA | Evidence Driven
CDA | Evidence Driven

Votrient for metastatic renal cell carcinoma - Details

Details

Files
Generic Name:
Pazopanib hydrochloride
Project Status:
Complete
Therapeutic Area:
Metastatic Renal Cell Carcinoma
Manufacturer:
GlaxoSmithKline Inc.
Brand Name:
Votrient
Project Line:
Reimbursement Review
Project Number:
PC0000-000
Performance Metric:
N/A — Predated performance metrics
Strength:
200 mg
Tumour Type:
Genitourinary
Indications:
Metastatic Renal Cell Carcinoma
Funding Request:
First-line therapy in patients with metastatic renal cell (clear cell) carcinoma who have a Memorial Sloan Kettering Prognostic Score of Favourable or Intermediate Risk
Review Status:
Complete
Sponsor:
GlaxoSmithKline Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse
pERC Meeting:
Final Recommendation Issued:

CLARIFICATION: The manufacturer, GlaxoSmithKline Inc. has resubmitted to pCODR for Pazopanib Hydrochloride (Votrient) submission. Please see the Pazopanib hydrochloride (Votrient) for Metastatic Renal Cell Carcinoma Resubmission Details page for more information.

Files

Provincial Funding Summary View PDF
Pazopanib (Votrient) for mRCC - pERC Final Recommendation Final Recommendation January 5, 2012 View PDF
Pazopanib (Votrient) for mRCC - Final Clinical Guidance Report Guidance Reports January 5, 2012 View PDF
Pazopanib (Votrient) for mRCC - Final Economic Guidance Report Guidance Reports January 5, 2012 View PDF
Pazopanib (Votrient) for mRCC - pERC Initial Recommendation Initial Recommendation November 3, 2011 View PDF
Pazopanib (Votrient) for mRCC - PAG Feedback on Initial Recommendation Feedback January 5, 2012 View PDF
Pazopanib (Votrient) for mRCC - Manufacturer (GlaxoSmithKline Inc.) Feedback on Initial Recommendation Feedback January 5, 2012 View PDF
Pazopanib (Votrient) for mRCC - Patient Advocacy Group (Kidney Cancer Canada) Feedback on Initial Recommendation Feedback January 5, 2012 View PDF
Pazopanib (Votrient) for mRCC - Patient Advocacy Group (Kidney Cancer Canada) COI Declarations Feedback January 5, 2012 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : January 20, 2012